A PHASE 2 RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, PROOF OF CONCEPT STUDY TO EVALUATE THE EFFICACY AND SAFETY OF VIB4920 IN SUBJECTS WITH SJOGREN'S SYNDROME (SS)

Administered By

Awarded By

Contributors

Start/End

  • April 2, 2020 - February 28, 2025